Product
RJMty19
Aliases
Cyclophosphamide, Fludarabine, RJMty19 (CD19-CAR-DNT cells)
2 clinical trials
2 indications
Indication
Systemic Lupus ErythematosusIndication
B-cell Non-Hodgkin's LymphomaClinical trial
A Phase I Clinical Trial of RJMty19 in Treatment of Subjects With Refractory Systemic Lupus ErythematosusStatus: Not yet recruiting, Estimated PCD: 2026-12-31
Clinical trial
A Phase 1, Open-label, Single Arm Clinical Trial to Evaluate the Tolerability, Safety and Efficacy of RJMty19 in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)Status: Not yet recruiting, Estimated PCD: 2025-05-20